BioCentury | May 18, 2015
Company News

Calchan neurology news

...was a senior director of clinical research at Pfizer Inc. (NYSE:PFE, New York, N.Y.). Calchan’s CNV2197944...
BioCentury | Jul 15, 2013
Clinical News

CNV2197944: Phase II started

...U.K.) began a double-blind, placebo-controlled, crossover, Hungarian Phase II trial to evaluate 75 mg oral CNV2197944...
...about 165 DPN patients. As part of its restructuring in 2011, Convergence transferred rights to CNV2197944...
...Convergence is developing the product on behalf of Calchan. Calchan Ltd. , London, U.K. Product: CNV2197944...
BioCentury | Apr 29, 2013
Clinical News

CNV2197944: Phase II started

...doses of oral CNV2197944. As part of its restructuring in 2011, Convergence transferred rights to CNV2197944...
...Convergence is developing the product on behalf of Calchan. Calchan Ltd. , Cambridge, U.K. Product: CNV2197944...
BioCentury | Jul 30, 2012
Clinical News

CNV2197944: Phase I data

...a placebo-controlled, U.K. Phase I trial in healthy volunteers showing that multiple ascending-doses of oral CNV2197944...
...its restructuring in 2011, Convergence transferred rights to CNV2197944 to Calchan. Convergence, which is developing CNV2197944...
...of the product to treat neuropathic pain in 2Q13. Calchan Ltd. , Cambridge, U.K. Product: CNV2197944...
BioCentury | Dec 5, 2011
Clinical News

CNV2197944: Phase I started

...ascending-doses of oral CNV2197944 for 28 days in about 50 healthy volunteers. Convergence is developing CNV2197944...
...of Calchan, which owns the rights to the compound. Calchan Ltd. , Cambridge, U.K. Product: CNV2197944...
BioCentury | Apr 18, 2011
Clinical News

CNV2197944: Phase I started

...single ascending-doses of oral CNV2197944 in 24 subjects. Convergence Pharmaceuticals Ltd. , Cambridge, U.K. Product: CNV2197944...
BioCentury | Oct 18, 2010
Emerging Company Profile

Convergence: Toning down pain

...well tolerated up to high doses in Phase I trials. Convergence's other clinical compound is CNV2197944...
BioCentury | Oct 4, 2010
Financial News

Convergence launches with $35.4 million

...channel voltage-dependent inhibitor that is preparing to begin Phase II testing in neuropathic pain; and CNV2197944...
Items per page:
1 - 8 of 8